Stockscreener 앱 받기
19.24
5.81%
-1.23
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com
IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha
IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com
FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com India
IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan
Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com
Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com
Nothing is Better Than Ideaya Biosciences Inc (IDYA) stock at the moment - Sete News
Ideaya Biosciences Inc (IDYA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
IDYA (Ideaya Biosciences Inc) has impressive results - uspostnews.com
Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - knoxdaily.com
Ideaya Biosciences Inc (NASDAQ: IDYA) Stock Forecast: An Analysis - Marketing Sentinel
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PR Newswire
IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences - Stock Titan
Envestnet Asset Management Inc. Sells 11,342 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences Grants Stock Options To New Employees Under 2023 Inducement Plan - Nasdaq
New PARG inhibitors disclosed in Ideaya patent - BioWorld MedTech
IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Analysts review Ideaya Biosciences Inc’s rating - knoxdaily.com
Ideaya Biosciences Inc (IDYA) shows promising results - uspostnews.com
Wells Fargo & Company MN Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event - marketscreener.com
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC (PR Newswire) - Aktiellt
JPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
(IDYA) Trading Report - news.stocktradersdaily.com
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
IDEAYA advances darovasertib in uveal melanoma trial By Investing.com - Investing.com Nigeria
Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell - marketscreener.com
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Ph - GuruFocus
IDEAYA advances darovasertib in uveal melanoma trial - Investing.com Australia
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - BioSpace
Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib - MarketScreener
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire) - Aktiellt
Wellington Management Group LLP Has $1.02 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Geode Capital Management LLC Acquires 43,226 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - The Malaysian Reserve
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - marketscreener.com
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and - GuruFocus
Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer - marketscreener.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
Raymond James Financial Inc. Takes Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Norges Bank Purchases Shares of 520,810 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - The AM Reporter
Vanguard Group Inc. Has $130.51 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya stock hits 52-week low at $14.09 amid market challenges By Investing.com - Investing.com South Africa
Ideaya stock hits 52-week low at $14.09 amid market challenges - Investing.com Australia
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events - BioSpace
KLP Kapitalforvaltning AS Makes New $383,000 Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences announces board change and new advisory role By Investing.com - Investing.com South Africa
IDEAYA Biosciences announces board change and new advisory role - Investing.com
2.92%
자본화:
|
볼륨(24시간):